تالیفات

 

THE 1996 SURVEY OF BEHCET'S DISEASE IN IRAN, STUDY OF 3153 CASES.

Authers: F. Shahram, F. Davatchi, M. Akbarian, F. Gharibdoost, A. Nadji, A. Jamshidi, H. Chams

Abstract: Behcet's disease (BD) is not ran in Iran. The annual incidence is around 345 patients for a population of 60 millions. The male/female ratio is 1. 13. The mean age at the onset of the disease is 26.2+9.7 years (CI at 95%=0 .4). The prevalence of clinical signs were as follow: Mucous membrane lesions 96%+0.7 (oral aphthosis 95.7%, genital aphthosis 64%); skin lesions 74%±I.5 (pseudofolliculitis 66%, erythema nodosum 23%): ocular ... سال انتشار: 1996
 

APLAR validation of Behcet’s disease (BD) diagnosis criteria, Iran experience.

Authers: F. Davatchi, F. Shahram, M. Akbarian, F. Gharibdoost, A. Nadji, C. Chams, H. Chams

Abstract: Considering that the majority of BD patients are from APLAR (Asia and Pacific League of Associations for Rheumatology) countries any diagnosis criteria for BD must have an adequate accuracy in these countries. The APLAR subcommittee for Behcet's Disease has set a prospective study to assess the accuracy of the existing diagnosis criteria. China, Iran, Japan, and Korea, the major countries with BD are participating to this study. The data from ... سال انتشار: 1996
 

Audiovestibular involvement in Behcet’s Disease (in patients with disease duration of more than 5 years).

Authers: F. Shahram, F. Sabeti, F. Davatchi, M. Khalessi, M. Akbarian, N. Shariati

Abstract: Introduction: We have previously shown that audio vestibular involvement is not frequent in early Behcet's disease (BD) at the time of diagnosis. This study was designed to clarify ­the frequency of audio vestibular involvement in patients with more chronic disease. Materials 8 Methods: We studied 60 BD patients with a disease duration of at least 5 years Patients were compared in a prospective study, to 28 controls (age and sex ... سال انتشار: 1996
 

Clinical Features of Behcet’s Disease in Children: A Collaborative Study of 86 cases.

Authers: I. Kone’-Paut, S. Yurdakul, S. Bahabri, N. Shafae, S. Ozen, H. Ozdogan, JL. Bernard

Abstract: We collected retrospectively clinical informations about a large series of 86 patients up to 16y of age, from 4 countries: Turquey (43), France (22), Saudi Arabia (11). Iran (10). All cases were first reviewed then 53 of them were selected according to the criteria of the International study group for BD. Statistical analysis: X2 square test and two tailed Fisher exact test. Descriptive data: males 45, females 41, sex ratio ... سال انتشار: 1996
 

Behcet’s disease and pregnancy.

Authers: A. Nadji, F. Shahram, F. Davatchi, M. Akbarian, F. Gharibdoost, A.R. Jamshidi

Abstract: Introduction: Behcet's disease (BD) is a multisystem disorder with potential ability to influence pregnancy outcome. Changes in the BD may also occur during pregnancy. This study was designed to find the effect of pregnancy on BD and the outcome of pregnancy. Materials & Methods: We analyzed 59 pregnancies in 54 women with BD. The disease activity during pregnancy and in the 6 month period both before pregnancy and after delivery were ... سال انتشار: 1996
 

Outcome analysis of ocular lesions in Behcet’s disease with six different therapeutic methods.

Authers: F. Davatchi, F. Shahram, F. Gharibdoost, M. Akbarian, A. Nadji, H. Chams, C. Chams

Abstract: Introduction: Ocular lesions are the major cause of morbidity in Behcet's Disease. If not treated, they usually progress toward severe loss of vision or blindness. Cytotoxic drugs are the main therapeutic arsenal used for this condition. Materials & Methods: in an open, non randomized control study. Pulse Cyclophosphamida (PCP), low dose pulse cyclophosphamide (LDP), oral cyclophosphamide (OCP). weakly methotrexate (MTX), chlorambucil (CHL), and cyclosporine A (CYA) were used in a standard ... سال انتشار: 1996
 

Behcet’s disease treatment.

Authers: C. Chams-Davatchi, F. Davatchi, F. Shahram

Abstract: There is not yet an effective treatment for all lesions of Behcet's disease and for all patients with Behcet's disease. The highest morbidity is from the ocular lesions. The mortality, although rare, is due to neurological and pulmonary involvement. Thrombosis of the large veins and arteries, also rare, may lead to morbidity and mortality. In daily practice, the best treatment for muco cutaneous lesions is colchicine. Thalidomide may be efficient ... سال انتشار: 1996
 

Proposed ocular Behcet therapeutic scoring and activity/chronicity ratio.

Authers: H. Chams, F. Shahram, F. Davatchi, M. Akbarian, F. Gharibdoost, A. Nadji, S. Chams

Abstract: The aim of this study is to propose a scoring system to determine the activity of the eyes, and to evaluate our medications in the treatment of ocular inflammation and vasculitis in Behect's disease (BD). Eleven activity and 5 chronicity (constant) parameters are scored from zero to 4 to consider the condition of each eye in Oculo-Behcet's disease. Both parameters are considered in our therapeutic scoring. The activity variables are: Episcleritis and/or ... سال انتشار: 1996
 

Cyclosporine in severe Ocular Lesions of Behcet’s Disease.

Authers: F. Shahram, F. Davatchi, H. Chams, M. Akbarian

Abstract: Introduction: There are several reports of good effects of Cyclosporine A (CsA) in the treatment of Behcet's disease (BD). We studied the long term effect of CsA in prospective open clinical trial on posterior uveitis (PU) and retinal vasculitis (RV) of BD. Materials & Methods: Twenty three patients with PU and/or RV diagnosed as BD (according to the Iran and to the Japan criteria) were selected. Initially CsA 5 mg/Kg/day orally ... سال انتشار: 1996
 

Cyclosporine in the treatment of severe ocular lesions of Behcet’s disease.

Authers: F. Gharibdoost, F. Shahram, F. Davatchi, H. Chams, M. Akbarian, A. Nadji

Abstract: Introduction: there are several reports of good effects of Cyclosporine A (Cs A) in the treatment of Behcet's disease (BD). We studied the long term effect, of A Cs A in a prospective open clinical trial on posterior uveitis (PU) and retinal vasculitis (RV) of BD. Materials & Methods: Twenty three patients with PU and / or RV diagnose as BD (according to the Iran and to the Japan criteria) ... سال انتشار: 1996
 

The Accuracy of IBDDAM in the Treatment Evaluation of Behcet’s Disease.

Authers: A.R. Jamshidi, F. Shahram, F. Davatchi, M. Akbarian, F. Gharibdoost, A. Nadji

Abstract: Introduction: Behcet's disease (BD) is characterized by recurrent attacks followed by remissions, making difficult the assessment of a given treatment. The aim of this study was to compare the Iran Behcet's Disease Dynamic Activity Measure (IBDDAM) with the physician's global assessment (PGA) in evaluating the treatment result. Materials & Methods: Ninety-six patients with BD were followed prospectively, regardless of their treatment modality. The range of follow up was 3 to 62 ... سال انتشار: 1996
 

Iran’s Aspect of Behcet’s Disease in Children, the 1996 Survey.

Authers: N. Shafaie, F. Shahram, A. Nadji, F. Davatchi, M. Akbarian, F. Gharibdoost, A.R. Jamshidi

Abstract: Introduction: There is considerable controversy in the characteristics of Behect's disease (BD) in children. The aim of this study is to show Iran's view m juvenile BD. Materials & Methods: Different manifestations of the disease were determined in the BD patients under the age of 16. They were compared with the adult patients by chi square test. Results: We had 102 children with BD. The male/female ratio was 1.04. Oral aphthosis (64%) ... سال انتشار: 1996
 

Effects of Suppressive Therapy with Levothyroxine on Bone Density.

Authers: B. Larijanie, F. Gharibdoost, M. Pajoohi, M. Bastanhagh, A. Sajadi, M. Shirzad, F. Davatchi

Abstract: Increased thyroid hormones level is associated with diminished bone density. It has been clarified that thyroid hormones by sirculating bone resorption lead to decrease in bone density. Thyroid hormone in many cases as in Non - Toxic Grotre & in supplement therapy in hypothyroidism is used as a drug & it is possible that suppressive therapy with T4 causes subclinical - hyperthyroidism. Studies done in west has shown different results ... سال انتشار: 1996
 

Outcome measurement of ocular lesions in Behcet’s disease.

Authers: F. Davatchi, S. Soroosh, F. Shahram, H. Chams, M. Akbarian, F. Gharibdoost, A. Nadji, C. Shams

Abstract: The outcome of ocular manifestations of Behcet’s Disease remains uncertain and unpredictable despite cytotxic drugs. One of our recent studies, presented to the 1995 Korean Rheumatology Annual Meeting, showed that one third of patients were None Responders, regardless of what treatment used. This study was designed to search for factors predicting the final outcome at the beginning of the treatment. Patients having more than one year of treatment were selected ... سال انتشار: 1996
 

Overview Of Pathogenesis & Management Of Behcet’s Disease.

Authers: F. Davatchi

Abstract: Genetic Background: Behcet’s Disease (BD) is known t0 be associated with the HLA-B5 gene. The association is with the B51subtype, the B*5101allele. The tryptophan amino acid in position 167 and histidine in position 171 seems to determine the susceptibility of B51 for BD. However all persons with B51 do not have BD and all BD patients do not have B51. Some particularity in the TNFβ gene region in BD patients ... سال انتشار: 1996
 

IN TIME VARIATION OF PATHERGY PHENOMENON IN BEHCET'S DISEASE.

Authers: C. Chams, F. Davatchi, F. Shahram, M. Akbarian, F. Gharibdoost, A. Nadji, A.R. Jamshidi

Abstract: The pathergy phenomenon (PP) is one of the hallmarks of Behcet's Disease (BD). It has been reported to be positive from 17.5% to 83% of cases in different studies. PP is used as a diagnosis criterion in the Dilsen criteria, the Japan criteria, the International criteria, and the Iran criteria. It is therefore important to know wether PP is a fix manifestation of the disease or a cyclic manifestation ... سال انتشار: 1996
 

Longitudinal study of the Pathergy phenomenon in Behcet’s Disease (BD).

Authers: C. Chams, F. Davatchi, F. Shahram, M. Akbarian, F. Gharibdoost, A. Nadji

Abstract: INTRODUCTION: The pathergy phenomenon (PP) is one of the hallmarks of Behcet's Disease (BD). It has been reported to be positive from 17.5% to 83% of cases in different studies. PP is used as a diagnosis criterion in the Dilsen criteria, the Japan criteria, the International criteria, and the Iran criteria. It is therefore important to know whether PP is a fix manifestation of the disease or a cyclic manifestation ... سال انتشار: 1996
 

Prolactin Level in Behcet’s Disease.

Authers: F. Shahram, F. Malek, F. Davatchi, M. Akbarian, F. Gharibdoost, A. Nadji

Abstract: Introduction: Prolactin (PRL) is an immune stimulating hormone and may be important in the pathogenesis of some autoimmune diseases, such as SLE. This study was designed to detect the PRL level in patients with Behcet's disease (BD), and its relation to the different manifestations of the disease. Materials & Methods: Thirty-seven new male patients with BD and 29 age matched control normal individuals (CON) was selected as every consecutive patient. The ... سال انتشار: 1996
 

Proposed ocular Behcet therapeutic scoring & activity/chronicity ratio.

Authers: H. Chams, F. Shahram, F. Davatchi, M. Akbarian, F. Gharibdoost, A. Nadji, S. Chams

Abstract: Behcet’s Unite, Shariati Hospital the aim to propose a scoring system for the treatment of the ocular inflammation one vasculitis by our medications and to evaluate the state of the activity of the eye. Eleven activity and five chronicity (constant) parameters are scored from zero to four to consider the condition of each eye. The activity variables are: episcleritis &/or scleritis, anterior uveitis, hyalites, IMU, central periphlebitis &/or thrombosis, central periartertis, peripheral ... سال انتشار: 1996
 

Treatment of Ophthalmologic Manifestations Of Behcet’s Disease Comparison Of 6 Methods.

Authers: F. Davatchi, F. Shahram, H. Chams, M. Akbarian, F. Gharibdoost, A. Nadji, C. Chams

Abstract: Introduction: Opthalmologic manifestations are the major cause of morbidity in Behcet’s Disease. If not treated, they usually progress toward sever loss of vision or blindness. Cytotoxic drugs are the main therapeutic agents. Materials & Methods: In an open, non randomized, control study, pulse cyclophosphamide (PCP), low dose pulse cyclophosphamide (LDP), weakly methtrexate (MTX), chlorambucil (CHL), oral cyclophosphamide (OCP), and cyclosporine A (CYA) were used in a standard protocol for 778 patients. ... سال انتشار: 1996
 

Treatment of Ocular Lesions in Behcet’s Disease (Outcome Analysis of Six Different Therapeutic Methods).

Authers: Farhad Shahram

Abstract: Introduction: Ocular lesions are the major cause of morbidity in Behcet’s Disease. If not treated they usually progress toward severe loss of vision or blindness. Cytotoxic drugs are the main therapeutic arsenal used for this condition. Materials & Methods: In an open, non randomized control study, pulse Cyclophosphamide (PCP), low dose pulse cyclophosphamide (LDP), oral cyclophosphamide (OCP), weakly methotrexate (MTX), chlorambucil (CHL), and cyclosporine A (CYA) were used in a standard ... سال انتشار: 1996